FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557038617> ?p ?o ?g. }

• W2557038617 abstract "Abstract Background: Iboctadekin (recombinant human IL-18) is an immunostimulatory cytokine with anti-tumor activity in preclinical animal models. Phase I clinical trials have demonstrated that IL-18 is well-tolerated as monotherapy or in combination with the CD20 monoclonal antibody (mAb) rituximab. In comparison to rituximab, the CD20 mAb ofatumumab has greater efficacy alone or in combination with IL-18 in SCID mouse models of lymphoma. Immunotherapy may be most effective against a minimal tumor burden, as can often be achieved after PBSCT for lymphoma. A phase I clinical trial was implemented to assess the safety and biologic activity of IL-18 in combination with ofatumumab after PBSCT for lymphoma. Methods: Patients with CD20+ B-cell non-Hodgkin lymphoma (NHL) were given ofatumumab 1000 mg IV weekly for 4 consecutive weeks in combination with IL-18 (in dose cohorts of 3, 10, and 30 mcg/kg) IV weekly for 8 weeks. Eligible patients had stable engraftment and disease that had not progressed after PBSCT. Assessments included safety/tolerability, pharmacokinetics, and pharmacodynamic studies (plasma cytokines, peripheral blood phenotypic markers). Results: Seven patients have been enrolled on study at a median of 133 days after PBSCT (range, 119 to 175 days), including 5 patients with relapsed (4) or primary refractory (1) diffuse large B cell lymphoma (DLBCL), 1 patient with indolent follicular NHL with transformation to aggressive lymphoma (relapsed), and 1 patient with mantle cell lymphoma (MCL) in first response. Three patients were enrolled in the 3 mcg/kg, 3 in the 10 mcg/kg, and 1 in the 30 mcg/kg dose cohorts, respectively. The combination of IL-18 and ofatumumab was well-tolerated with a safety profile similar to that observed with IL-18 plus rituximab given for relapsed/refractory NHL. All 7 patients received the planned 4 doses of ofatumumab. Five patients received the planned 8 doses (1 at 3 mcg/kg, 3 at 10 mcg/kg, 1 at 30 mcg/kg) of IL-18. The patient with MCL was taken off study for disease progression after receiving 6 doses (at 1 mcg/kg) of IL-18. One patient with relapsed DLBCL received only 6 of 8 doses (at 1 mcg/kg) of IL-18 due to occurrence of grade 3 neutropenia, which resolved after IL-18 was stopped. Like other immunostimulatory cytokines such as IL-12, IL-18 causes transient lymphopenia due to activation of lymphocytes with subsequent extravasation to tissue sites (J. Immunother 2013; 36: 331-341). Absolute lymphocyte counts (ALC) transiently decreased by a median of 89% (range, 50%-93%) after the first infusion of IL-18 on this study. ALC decreased by a median of 60% in the 3 mcg/kg dose cohort of patients as compared to 93% in the 10 mcg/kg cohort. Absolute natural killer (NK) cell counts transiently decreased by a median of 93% (range, 89%-98%) after the first infusion of IL-18. Increases in activated (CD69+) T or NK cells were not detected by flow cytometry in the peripheral blood of 2 patients during study drug administration. In peripheral blood of 5 patients the absolute number of CD69+ NK cells increased by a median of 4.3-fold (range, 1.2-5.6-fold) and the absolute number of CD69+ T cells increased by a median of 2.6-fold (range, 1.1-5.9-fold). Plasma cytokine levels (including IFN-gamma) are being measured by ELISA and data will be presented. At a median follow-up of 17+ months post-PBSCT (range, 7+ to 25+ months), all 6 patients with aggressive NHL (5 DLBCL, 1 transformed aggressive from indolent follicular lymphoma) are alive and free of disease progression. Conclusions: The combination of IL-18 and ofatumumab is safe, well-tolerated, and induces expected biological activity after PBSCT. A maximum tolerated dose of IL-18 has not been identified. Accrual to the 30 mcg/kg IL-18 dose cohort is ongoing. Further studies of IL-18 plus CD20 mAb in patients with B cell NHL are warranted. Disclosures Robertson: Eli Lilly: Equity Ownership. Off Label Use: IL-18 and ofatumumab are not approved by FDA for use in treatment of lymphoma." @default.
• W2557038617 created "2016-11-30" @default.
• W2557038617 creator A5003349135 @default.
• W2557038617 creator A5016721473 @default.
• W2557038617 creator A5057331792 @default.
• W2557038617 creator A5060774368 @default.
• W2557038617 creator A5076249181 @default.
• W2557038617 date "2015-12-03" @default.
• W2557038617 modified "2023-10-01" @default.
• W2557038617 title "Phase I Study of Recombinant Human Interleukin-18 (IL-18) in Combination with Ofatumumab after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoma" @default.
• W2557038617 doi "https://doi.org/10.1182/blood.v126.23.5102.5102" @default.
• W2557038617 hasPublicationYear "2015" @default.
• W2557038617 type Work @default.
• W2557038617 sameAs 2557038617 @default.
• W2557038617 citedByCount "0" @default.
• W2557038617 crossrefType "journal-article" @default.
• W2557038617 hasAuthorship W2557038617A5003349135 @default.
• W2557038617 hasAuthorship W2557038617A5016721473 @default.
• W2557038617 hasAuthorship W2557038617A5057331792 @default.
• W2557038617 hasAuthorship W2557038617A5060774368 @default.
• W2557038617 hasAuthorship W2557038617A5076249181 @default.
• W2557038617 hasConcept C126322002 @default.
• W2557038617 hasConcept C143998085 @default.
• W2557038617 hasConcept C18031839 @default.
• W2557038617 hasConcept C203014093 @default.
• W2557038617 hasConcept C2777058707 @default.
• W2557038617 hasConcept C2777525834 @default.
• W2557038617 hasConcept C2778559949 @default.
• W2557038617 hasConcept C2778714382 @default.
• W2557038617 hasConcept C2779338263 @default.
• W2557038617 hasConcept C2780653079 @default.
• W2557038617 hasConcept C2781214270 @default.
• W2557038617 hasConcept C2911091166 @default.
• W2557038617 hasConcept C31760486 @default.
• W2557038617 hasConcept C535046627 @default.
• W2557038617 hasConcept C71924100 @default.
• W2557038617 hasConcept C90924648 @default.
• W2557038617 hasConceptScore W2557038617C126322002 @default.
• W2557038617 hasConceptScore W2557038617C143998085 @default.
• W2557038617 hasConceptScore W2557038617C18031839 @default.
• W2557038617 hasConceptScore W2557038617C203014093 @default.
• W2557038617 hasConceptScore W2557038617C2777058707 @default.
• W2557038617 hasConceptScore W2557038617C2777525834 @default.
• W2557038617 hasConceptScore W2557038617C2778559949 @default.
• W2557038617 hasConceptScore W2557038617C2778714382 @default.
• W2557038617 hasConceptScore W2557038617C2779338263 @default.
• W2557038617 hasConceptScore W2557038617C2780653079 @default.
• W2557038617 hasConceptScore W2557038617C2781214270 @default.
• W2557038617 hasConceptScore W2557038617C2911091166 @default.
• W2557038617 hasConceptScore W2557038617C31760486 @default.
• W2557038617 hasConceptScore W2557038617C535046627 @default.
• W2557038617 hasConceptScore W2557038617C71924100 @default.
• W2557038617 hasConceptScore W2557038617C90924648 @default.
• W2557038617 hasLocation W25570386171 @default.
• W2557038617 hasOpenAccess W2557038617 @default.
• W2557038617 hasPrimaryLocation W25570386171 @default.
• W2557038617 hasRelatedWork W2548244535 @default.
• W2557038617 hasRelatedWork W2549152338 @default.
• W2557038617 hasRelatedWork W2552616922 @default.
• W2557038617 hasRelatedWork W2560281006 @default.
• W2557038617 hasRelatedWork W2561425732 @default.
• W2557038617 hasRelatedWork W2566067846 @default.
• W2557038617 hasRelatedWork W2567779130 @default.
• W2557038617 hasRelatedWork W2573030598 @default.
• W2557038617 hasRelatedWork W2576020159 @default.
• W2557038617 hasRelatedWork W2592669981 @default.
• W2557038617 hasRelatedWork W2593800067 @default.
• W2557038617 hasRelatedWork W2736149368 @default.
• W2557038617 hasRelatedWork W2756049805 @default.
• W2557038617 hasRelatedWork W2972293235 @default.
• W2557038617 hasRelatedWork W2980363913 @default.
• W2557038617 hasRelatedWork W2980947982 @default.
• W2557038617 hasRelatedWork W2988060344 @default.
• W2557038617 hasRelatedWork W3076749343 @default.
• W2557038617 hasRelatedWork W3096297243 @default.
• W2557038617 hasRelatedWork W3209602221 @default.
• W2557038617 isParatext "false" @default.
• W2557038617 isRetracted "false" @default.
• W2557038617 magId "2557038617" @default.
• W2557038617 workType "article" @default.